statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New MultiCenter Prospective Study Demonstrates Signateras Clinical Utility in Merkel Cell Carcinoma

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncology highlighting the utility of its personalized and...

(NTRA) - Analyzing Natera's Short Interest

Here's How Much You Would Have Made Owning Natera Stock In The Last 5 Years

Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and reproductive genetics will be presented at...

Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new gastroesophageal cancer trial, DECIPHER, that will utilize the companys personalized...

$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today

Natera Launches Differentiated New Feature for Prospera Heart Test, Enhancing Detection of Rejection for Transplant Patients

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart with Donor Quantity Score (DQS), further enhancing Prosperas...

Final Trades: Amazon, Natera and KKR

Breaking Down Natera: 10 Analysts Share Their Views

Latest Ratings for NTRA
 DateFirmActionFromTo Mar 2022Goldman SachsInitiates Coverage OnBuy Feb 2022Morgan StanleyMaintainsOverweight Feb 2022BairdMaintainsOutperform
 View More Analyst Ratings...

Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June...

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Natera Inc

Volume	1.05M
52-Wk High	$117.23
52-Wk Low	$36.90

NTRA Natera Inc

About

Feed

News

Sentiment

Earnings

Fundamentals